Skip to main content
Fanli Digital Technology Co., Ltd logo

Fanli Digital Technology Co., Ltd — Investor Relations & Filings

Ticker · 600228 ISIN · CNE000000Y78 Shanghai Stock Exchange Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 2,248 across all filing types
Latest filing 2021-01-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600228

About Fanli Digital Technology Co., Ltd

https://corp.fanli.com/

Fanli Digital Technology Co., Ltd. provides e-commerce integration and digital marketing services. The company operates a comprehensive platform that connects consumers with various online retail ecosystems through value-added services such as cash-back rewards, discount coupons, and promotional insights. Its core business model focuses on performance-based marketing, utilizing data-driven strategies to facilitate sales conversions for brand partners. Key offerings include brand promotion, user loyalty management, and targeted advertising solutions. By integrating diverse shopping channels into a single interface, the company optimizes the consumer purchasing journey and provides brands with scalable traffic acquisition tools. The platform serves as a strategic intermediary, leveraging user behavioral data to enhance marketing efficiency and provide measurable returns for merchants while delivering cost savings to a broad user base.

Recent filings

Filing Released Lang Actions
上海中彦信息科技股份有限公司《﹤关于江西昌九生物化工股份有限公司股票交易异常波动的询证函﹥的回函》
Regulatory Filings
2021-01-20 Chinese
北京市文化中心建设发展基金管理有限公司《﹤关于江西昌九生物化工股份有限公司股票交易异常波动的询证函﹥的回函》
Regulatory Filings
2021-01-20 Chinese
杭州同美股权投资基金合伙企业（有限合伙）《﹤关于江西昌九生物化工股份有限公司股票交易异常波动的询证函﹥的回函》
Regulatory Filings
2021-01-20 Chinese
上海文心智合企业发展有限公司《﹤关于江西昌九生物化工股份有限公司股票交易异常波动的询证函﹥的回函》
Regulatory Filings
2021-01-20 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement by Jiangxi Changjiu Biochemical Co., Ltd. regarding abnormal stock price fluctuations over three consecutive trading days in January 2021. It details the company's investigation into the causes, confirms no undisclosed material information beyond a major asset restructuring, and discusses related risks. The document references regulatory bodies such as the China Securities Regulatory Commission and the Shanghai Stock Exchange, and includes dates and details about the asset restructuring process and regulatory approvals. The content is focused on stock trading abnormality disclosure and risk warnings rather than financial statements or earnings data. It is not a full financial report, audit report, or earnings release. It is also not a simple announcement of a report publication but a substantive regulatory disclosure about stock price abnormality and related corporate events. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-01-20 Chinese
关于收到《中国证监会行政许可申请中止审查通知书》暨公司重大资产重组中止事项提示的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the receipt of a notice from the China Securities Regulatory Commission (CSRC) about the suspension of the review process for the company's major asset restructuring administrative license application. It details the status of the major asset restructuring, the reasons for the suspension, assurances that the restructuring is ongoing and not terminated, and the company's plans to resume the process. The document is regulatory in nature, providing updates on a significant corporate event related to a major asset restructuring and administrative procedures with the regulator. It does not contain financial statements, audit results, or detailed financial data. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or earnings release. It is an official regulatory announcement about the status of a major corporate transaction and regulatory approval process. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-01-20 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.